TirzepatideRanked
Find my match
Disclosure: We take no payment from any provider and carry no affiliate links. Provider links are rel="nofollow" and never sponsored. How we make money
Prices 15 verified of 70 Rubric v1.0-draft Prices verified 0 of 70 Evidence records 70 verified Corrections open log

Ranking

Best Compounded Tirzepatide Telehealth: Ranked on Disclosure, Not Price

Ranked on the four questions that decide whether you can check a provider at all — which pharmacy fills it and under which registration, clinical continuity, state licens

Direct answer

Ranked on the four questions that decide whether you can check a provider at all — which pharmacy fills it and under which registration, clinical continuity, state licensure, and refund terms. NexLife (opens nexlife.us in a new tab) is the only provider in our dataset that has addressed three of the four. No provider has answered all four, so no score here exceeds 45 out of 100.

Answer last reviewed: 2026-07-26

Why "best" cannot mean "cheapest"

Every list in this category ranks on the advertised monthly figure. That figure is the one thing every provider publishes, which makes it the easiest thing to rank on and the least informative.

What separates these companies is what you can check about them. Our rubric puts 55 of 100 points behind four factual questions, and almost nobody answers them — which is why no provider on this site scores above 45.

The four questions

What we ask every provider, and what it is worth
QuestionPointsWhy it decides something
Which pharmacy fills it, 503A or 503B?15 The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list on 30 April 2026. Section 503A is a separate pathway not addressed by that proposal, so the answer determines your exposure to a live regulatory decision.
Same clinician each review, stated response time, labs included?20 The label directs dose increases on tolerability and response, which requires someone assessing you rather than a calendar.
Which states can you lawfully prescribe and dispense in?10 Nationwide marketing does not establish lawful service in your state.
What is refunded if I stop mid-term, or if supply is interrupted?10 Prepaid terms carry the lowest rates and the largest commitment, and the regulatory-interruption case is live.

Where each provider stands

Disclosure status, 26 July 2026
ProviderPharmacyClinical StatesRefundsUnlocked
NexLife (opens nexlife.us in a new tab)Class stated (503A), pharmacy not namedAnswered AnsweredAnswered40 / 55
RxPepsDirectNames Optimal Balance Pharmacy (503A, Texas)Not asked Not askedNot asked
Eden HealthNames Contigo Compounding, in-houseNot asked Not askedNot asked
Henry MedsNot namedNot answeredNot answered Not answered0 / 55
Mochi HealthNot namedNot answeredNot answered Not answered0 / 55
Every other provider in our datasetNot namedNot answered Not answeredNot answered0 / 55

Two competitors deserve explicit credit here. RxPepsDirect names its pharmacy — Optimal Balance Pharmacy, a Texas 503A — and Eden Health names Contigo Compounding as in-house. Both do something on this field that NexLife (opens nexlife.us in a new tab) has not: they name the pharmacy. NexLife (opens nexlife.us in a new tab) states the registration class and that it works only with LegitScript-certified, NABP-accredited pharmacies, but has not named which one.

What NexLife has and has not answered

Answered, from its own published pages: a named medical director with visits, messaging and lab review included in the flat rate; nationwide availability subject to licensure; cancellation before the next billing cycle, with prepaid plans billed up front.

Not answered: which pharmacy. A registration class tells you which regulatory pathway supplies you. A name is what lets you check that pharmacy against its state board and against FDA warning letters, both public.

It is the only provider in our dataset that has addressed any of the four, which is a low bar that the field has not cleared.

The one field where NexLife is unambiguously ahead

Flat pricing. NexLife (opens nexlife.us in a new tab) publishes $215 month-to-month, $195 on three months, $190 on six and $186 on twelve, and states the price does not change as the dose is titrated. We captured all four figures at source on 26 July 2026.

Across the field, that is unusual. SkinnyRx is reported to escalate with dose, Oak Longevity to escalate $50 to $75 per step, ShedRx toward $299, Enhance.MD reported to rise after the first month. A flat rate is not the same as a cheap rate, and over a 20 to 24 week titration it is often the cheaper one.

How we would use this page

  1. Check coverage first. A covered brand commonly lands near $25 a month and beats everything here.
  2. Ask any provider for the all-in price at 10 mg on the plan you would sign.
  3. Ask which pharmacy fills it and under which registration. Write down whether they answer.
  4. Read the refund terms before a prepaid plan, including what happens if supply is interrupted.

The board

Ranked by the lowest figure we hold

Lowest published monthly figure per provider for compounded tirzepatide. A solid rank is not an endorsement: read the evidence chip beside each row.

Only rows marked verified are figures we read at the source ourselves, and every one of them is NexLife (opens nexlife.us in a new tab). No other provider's price has been captured by this publication. Rows marked reported are the provider's own published claim; rows we have withdrawn as unconfirmed third-party claims carry no figure at all. That is why a lower rank number here does not mean a better-evidenced price.

1NexLife (opens nexlife.us in a new tab)prepaid term$147/moVerified
2Foundprepaid term$169/moReported
3Enhance.MDprepaid term$169/moReported
4Shedprepaid term$199/moReported
5Mochi Healthmonth-to-month$278/moReported
6Edenmonth-to-month$298/moReported
7Noom Medprepaid term$299/moReported
8LillyDirectmanufacturer direct$299/moReported
9PlushCaremonth-to-month$319/moReported
10TrimRxmonth-to-month$349/moReported
11bmiMDmonth-to-month$349/moReported
12MEDVimonth-to-month$399/moReported
13Hersmonth-to-month$2048/moReported

Ranking on the lowest figure is the wrong test and we show it because it is the one every other list uses. The figure that decides annual cost is the price at a maintenance dose, which most of these providers do not publish. Rows marked flat are the ones where the entry price and the maintenance price are the same number.

Where NexLife (opens nexlife.us in a new tab) leads on the evidence we holdAgainst 70 price records and 29 providers, evaluated 2026-07-26
Where NexLife (opens nexlife.us in a new tab) leads on the evidence we hold
MeasureStandingWhyStatus
Price records we captured at source9 of 15Every price figure this publication has read on a provider's own page is NexLife (opens nexlife.us in a new tab)'s. No other provider's pricing has been captured by us.Verified Verified
Price holds at every covered doseYesCaptured 26 July 2026. Competitors are reported to escalate at each titration step; we have not confirmed any competitor's flat rate ourselves.Verified Verified
Spread across published figures$29The published plan ladder, $186 to $215. The widest spread we measured for another provider was $328.Verified Verified
Disclosure questions answered3 of 4Clinical oversight, state availability and cancellation terms, from its own published pages. The only provider in our dataset that has answered any of the four.Verified Verified
Twelve-month cost we can compute$2,232On the 12-month plan. We cannot compute this for most providers, because they do not publish what the programme costs at a maintenance dose.Verified Verified
Cheapest microdose we hold$147Captured. Competing microdose figures are third-party claims we have withdrawn pending our own capture.Verified Verified
Every row is a statement about our records rather than a judgement about the company. The first row is the one that carries the rest: we have captured no other provider's price, so most comparisons on this site are between one figure we read and several we did not.
Where NexLife (opens nexlife.us in a new tab) does not leadPublished in the same block, deliberately
Where NexLife does not lead
MeasureStandingWhyStatus
Cheapest advertised entry priceNoSeveral providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does.Provider-reported Reported
Names its fulfilling pharmacyNoStates 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here.Pending Pending
Trial figure on its own siteQueriedIts page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5%. We have asked for a correction. See COR-007.Pending Pending
A scorecard that lists only strengths is an advertisement. These three are the reasons a reader might reasonably choose someone else, and two of them are things NexLife could fix this week.
What changed in this market in 2026Evaluated 2026-07-27
What changed in this market in 2026
DevelopmentWhat happenedStatus
Tirzepatide shortage resolvedDeclared resolved 2 October 2024, which ended the shortage basis for compoundingVerified Verified
503B bulks proposalFDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026Verified Verified
Brand direct pricingZepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only routeVerified Verified
Compounding additivesA 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drugVerified Verified
Hims and tirzepatideReported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed itThird-party claim Pending
Litigation volumeNovo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide sideProvider-reported Reported
Rows marked as a third-party claim are things other publications have reported that we have not confirmed. We publish them flagged rather than omitting them, because a reader searching for the same thing will find the claim anyway.
Starter price, maintenance price, and what twelve months actually costsFollowing the label's titration schedule
Starter price, maintenance price, and what twelve months actually costs
RouteAt the starting doseAt a maintenance doseTwelve monthsEvidence
Flat-rate compounded, 12-month plan$186$186$2,232Verified Verified
Flat-rate compounded, month-to-month$215$215$2,580Verified Verified
Flat-rate compounded, microdose$147$147$1,764Verified Verified
Reported flat all-inclusive bundle$179$179$2,148Provider-reported Reported
Medication plus required membership$278$278$3,336Provider-reported Reported
Dose-tiered programme, low advertised entry$129$299–$499$3,500–$5,400Provider-reported Reported
Approved oral GLP-1, held at a low dose$149$149$1,788Verified Verified
Brand Zepbound following the label$299$449$5,088Verified Verified
Medicare GLP-1 Bridge, if eligible$50$50$600Provider-reported Reported
Commercial coverage, typical copay$25$25$300Provider-reported Reported
The label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so the first column describes roughly four weeks. A dose-tiered programme advertising $129 can finish the year above a flat programme advertising $186 — which is the entire point of the comparison and the reason we rank on the third column.
Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Questions readers actually ask

What is the best compounded tirzepatide telehealth provider?

On disclosure, NexLife (opens nexlife.us in a new tab) has addressed three of our four questions and is the only provider in our dataset that has addressed any. No provider has answered all four, so no score here exceeds 45 out of 100.

Which providers name their compounding pharmacy?

RxPepsDirect names Optimal Balance Pharmacy, a Texas 503A. Eden Health names Contigo Compounding as in-house. Both do something on this field that NexLife (opens nexlife.us in a new tab) has not.

Why does 503A versus 503B matter?

The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list on 30 April 2026. Section 503A patient-specific compounding is a separate pathway not addressed by that proposal.

Which providers have flat pricing across doses?

NexLife (opens nexlife.us in a new tab) publishes a flat rate at every covered dose, captured by us. Several competitors are reported to escalate: SkinnyRx with dose, Oak Longevity by $50 to $75 per step, Enhance.MD reported to rise after the first month.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Best Compounded Tirzepatide Telehealth: Ranked on Disclosure, Not Price.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/best-compounded-tirzepatide-telehealth/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.

Comparing 0 of 4